NICE TA1121 recommends acoramidis and formalises a comparator-bridge evidence standard in transthyretin cardiomyopathy

NICE recommended acoramidis for transthyretin amyloidosis with cardiomyopathy on 14 January 2026, using indirect comparative evidence to position acoramidis against tafamidis in routine NHS use.